Iloprost enhances portal flow velocity and volume in patients with systemic sclerosis

BACKGROUND: Iloprost, a prostacyclin analog, reduces hepatic microcirculatorydamage after ischemia-reperfusion injury in animal liver models. The objective ofthis study was to evaluate whether the portal flow velocity changes afterIloprost infusion in patients with systemic sclerosis and Raynaud's phenomenon,who usually have increased risk of microvascular thrombosis and transient liverdisturbances.PATIENTS AND METHODS: Fifteen patients (3 males and 12 females, median age 58 years, range 47-66 years), with systemic sclerosis and Raynaud's phenomenon, wereexclusively treated with an infusion of Iloprost (2 ng/kg/min, 6 h/day) for 5days. In each subject, the portal flow velocity (PV, cm/sec) and portal flowvolume (PFV, mL/min) were obtained by using portal color Doppler ultrasonography equipment.RESULTS: Iloprost administration significantly (p<0.001) increased both the PV (23.6+/-3.4 cmlsec vs. 29.1+/-3.9 cm/sec) and PFV (1748.8+/-310. 7 mL/min vs.2254.9+/-404.1 mL/min) values.CONCLUSION: Hepatic perfusion significantly improved after Iloprost administration, suggesting that such treatment might be useful in preventing vascular complications in patients with systemic sclerosis. Iloprost improves theportal hemodynamics, favoring local microvascular patency, and its effectiveness may be safely monitored by using portal color Doppler ultrasonography